BIOS Capital Management, LP
Fort Worth, TX
$42m in 6 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 15.4% of the portfolio this quarter.
Value
$42m
Stocks
6
Top 10 share
100.0%
Turnover
15.4%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
- Rein TherapeuticsRNTX7.4% of the fund+50%
Cut
Sold some of their stake.
- Lantern PharmaLTRN2.5% of the fund-71%
- In8bioINAB0.3% of the fund-52%
Sold out
Sold their entire stake.
None this quarter.
Holdings
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Actuate TherapeuticsACTU | 36.9% | $15m | 10,049,996 | Held |
| Opus GeneticsIRD | 36.3% | $15m | 3,683,429 | Held |
| Cognition TherapeuticsCGTX | 16.6% | $7m | 6,000,000 | Held |
| Rein TherapeuticsRNTX | 7.4% | $3m | 2,982,375 | +50% |
| Lantern PharmaLTRN | 2.5% | $1m | 249,397 | -71% |
| In8bioINAB | 0.3% | $114,149 | 80,957 | -52% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is down 42.6% since 30 June 2025.
Where the money is
Health care100.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.